Register for OBR daily


IMS_White_300x250

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

IMUC $1.00 0.0794 +8.62%
CYTK $4.14 0.2800 +7.25%
AVEO $1.27 0.0800 +6.72%
DNDN $1.50 0.0800 +5.63%
PPHM $1.46 0.0700 +5.04%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

NYMX $4.15 -0.6000 -12.63%
XNCR $9.69 -0.7700 -7.36%
RNN $0.71 -0.0531 -6.99%
OGXI $2.80 -0.2000 -6.67%
ONCY $0.73 -0.0500 -6.41%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | Next > | Last >>

What Cancer Patients Want and What Medicare Covers May Differ

(Reuters Health) Sept 10, 2014 - When asked what Medicare should cover for cancer patients in their last months of life, many patients and their caregivers choose benefits the federal insurance does not offer, like home-based long term care and concurrent palliative care, according to a new study based on interviews.
read article 



U.S. FDA Approves Expanded Use of Medivation Prostate Cancer Drug

(Reuters) Sept 10, 2014 - U.S. health regulators approved the use of Medivation Inc's and Astellas Pharma Inc's advanced prostate cancer drug Xtandi in men who have not yet received chemotherapy, the companies said on Wednesday, significantly expanding the potential patient population for the oral medicine.
read article 



FDA Advisors: No to Nebivolol/Valsartan Combo Pill for HTN

(Medscape Medical News) Sept 10, 2014 - An FDA advisory panel has recommended by a six-to-four vote that a dual-agent medication combining a beta-blocker and an angiotensin-receptor blocker (ARB) not be approved for the treatment of hypertension.
read article (free registration required) 



University Plan to Review Clinical Trial Work Meets Conflict Charges

(Wall Street Journal/Pharmalot blog) Sept 10, 2014 - Hiring the Association for the Accreditation of Human Research Protection Programs to review clinical trial practices is proving controversial for the University of Minnesota.
read article (paid subscription required) 



FDA Staff Review of NPS Drug Sparks Stock Rebound

(Reuters) Sept 10, 2014 - NPS Pharmaceuticals Inc's hormone replacement therapy Natpara appears effective, though data from one clinical trial site was excluded due to manufacturing violations, according to a preliminary report by the U.S. Food and Drug Administration.
read article 



A New Cancer Drug Worked In Over 25% Of Patients In A Phase I Trial

(Forbes) Sept 10, 2014 - The new cancer drug CPI-613, made by Cornerstone Pharmaceuticals, benefited 29 percent of cancer patients during a phase I trial at Wake Forest Baptist Medical Center, even putting one patient with myelodysplastic syndrome in a complete remission that has lasted for more than three years.
read article 



ASH Comments on Proposals Covering Medicare Payments to Physicians and Hospitals in 2015

(ASH) Sept 9, 2014 - On August 29, 2014, ASH submitted comment letters covering Medicare proposals for payments and associated policies for services paid under the physician fee schedule and the hospital outpatient prospective payment system. ASH analyzed the physician fee schedule and hospital outpatient rule when they were released in July.
read article 



Workshop: Innovations in Breast Cancer Drug Development

(ASCO in Action) Sept 9, 2014 - ASCO, the U.S. Food and Drug Administration, the American Association for Cancer Research, and the Breast Cancer Research Foundation are sponsoring a public Breast Cancer Workshop on Oct. 21, 2014, at the Hyatt Regency Bethesda in Bethesda, Maryland.
read article 



CancerLinQ™ Receives Major Commitment from CTCA®

(ASCO in Action) Sept 9, 2014 - The Conquer Cancer Foundation of ASCO has received a major commitment of support for the development of CancerLinQ™ from Cancer Treatment Centers of America, Inc. (CTCA), a national network of five cancer hospitals.
read article 



Louis J. DeGennaro, Ph.D., Named President and Chief Executive Officer of The Leukemia & Lymphoma Society

(LLS.org) Sept 9, 2014 - The Leukemia & Lymphoma Society (LLS) announced today that Louis J. DeGennaro, Ph.D., has been appointed as president and chief executive officer, effective immediately.
read press release 



Red Carpet Paves Way to Research $$$

(MedPage Today) Sept 9, 2014 - Viewers of Stand Up To Cancer's (SU2C) fourth 1-hour live prime-time commercial-free program -- telecast over more than 30 broadcast and cable networks Friday night -- pledged more than $109 million, with about $82 million slated for translational cancer research projects in the U.S. and about $27 million for Canadian researchers.
read article (free registration required) 



Leading Radiation Oncologists Chosen to Present at Annual Conference

(PRWeb) Sept 10, 2014 - Several physicians with 21st Century Oncology, the nation's premier cancer treatment network and largest radiation therapy provider, have been chosen to showcase their latest research developments at The American Society for Radiation Oncology (ASTRO) 56th annual meeting.
read press release 



Cancer Drugs Fund Is Just Smoke and Mirrors

(PharmaTimes [UK]) Sept 10, 2014 - The new cash injection into the Cancer Drugs Fund is just political “smoke and mirrors”, and there will be no incentive for pharma to reduce its drug prices, a leading cancer expert has said.
read article 



A Survivorship Roadmap Linked to EMRs

(ACCCBuzz) Sept 9, 2014 - In a perfect world each patient who has recently completed cancer-directed therapy should receive a survivorship care plan that clearly summarizes his or her treatment and provides direction on what to expect in the next several weeks, months, and years of their life to come.
read article 



NanoString Introduces Novel Gene Expression Panel for Immuno-Oncology Research

(NanoString Technologies) Sept 9, 2014 - NanoString Technologies, Inc. today announced the introduction of a new highly multiplexed gene expression panel for the nCounter® Analysis System, the PanCancer Immune Profiling Panel.
read corporate press release 



Pathway Genomics Launches BreastTrue NGS High Risk Breast Cancer Panel with PALB2

(Yahoo! Finance UK) Sept 10, 2014 - Pathway Genomics Corporation today announced it has launched BreastTrueTM High Risk Panel, a blood or saliva next-generation sequencing test with deletion/duplication analysis to detect mutations in seven high-risk breast cancer susceptibility genes, including BRCA1, BRCA2 and PALB2.
read article 



MabVax Therapeutics Enters Agreements with Memorial Sloan Kettering Cancer Center and Juno Therapeutics for Development of Anti-Cancer Therapeutics

(San Francisco Business Times) Sept 10, 2014 - MabVax Therapeutics Holdings, Inc. announced today it has entered into agreements with Memorial Sloan Kettering Cancer Center (MSK) and Juno Therapeutics (Juno) for the development of novel therapeutic products using antibody targeting sequences derived from the fully-human antibodies discovered using the Company's internally developed antibody discovery platform.
read article 



Seattle Genetics and Genmab Enter Into New Antibody-Drug Conjugate Collaboration

(NBC News) Sept 10, 2014 - Seattle Genetics, Inc. and Genmab A/S today announced that the companies have entered into an additional antibody-drug conjugate (ADC) collaboration.
read article 



Nymox Announces Positive Prostate Cancer 8 Month Clinical Trial Results

(CNN Money) Sept 10, 2014 - Nymox Pharmaceutical Corporation announced today new positive outcome results from the Company's ongoing prospective NX03-0040 trial of NX-1207 for the treatment of low grade localized prostate cancer.
read article 



Monitoring the Response of Bone Metastases to Treatment Using MRI and PET

(EORTC) Sept 10, 2014 - A review and position statement of the EORTC Imaging Group.
read article 



Researchers Unlock the Genetic Code of Cancer-Causing Liver Fluke Parasite

(A*STAR [Singapore]) Sept 10, 2014 - An international team of scientists from Singapore, Thailand, China and Australia has cracked the genetic code of the liver fluke parasite, Opisthorchis viverrini, using a unique DNA analysis technique developed at A*STAR’s Genome Institute of Singapore (GIS).
read press release 



Gobbling Up Poison: A Method for Killing Colon Cancer

(Thomas Jefferson University) Sept 9, 2014 - A new Immunotoxin works by getting shuttled into cancer cells, selectively destroying colon cancer, thanks to a quirk of biology.
read press release 



Battling Breast Cancer: U.Va. Pioneers Image-Guided, High-Dose Approach

(UVA Today/University of Virginia) Sept 9, 2014 - An experimental approach to treating breast cancer being tested at the University of Virginia Health System allows doctors to administer significantly higher doses of cancer-killing radiation where it’s needed at the same time as tumor removal while sparing healthy tissue, an initial research study suggests.
read article 



'Electronic Skin’ Could Improve Early Breast Cancer Detection

(American Chemical Society) Sept 10, 2014 - Scientists are now developing an “electronic skin” that “feels” and images small lumps that fingers can miss during manual breast cancer exams.
read press release 



Olaparib Tablet Safe in Pretreated Ovarian Cancer Patients; More Effective in Those with BRCA Mutations

(AACR) Sept 9, 2014 - An oral tablet form of a PARP inhibitor, olaparib, given in combination with chemotherapy, was safe in heavily pretreated ovarian cancer patients, and patients with BRCA mutations may have a better response compared with those without a BRCA mutation, according to phase Ib clinical trial data.
read press release